Core Viewpoint - Supernus Pharmaceuticals has undergone a significant transformation into a diversified CNS (Central Nervous System) growth company, with a current enterprise value of up to $3 billion [2][3]. Company Overview - Supernus Pharmaceuticals was founded as a spinout of Shire in 2005, marking its 20-year anniversary [3]. - The company is led by Jack Khattar, who has a strong operational track record [2]. Analyst Perspective - The lead analyst, Pavan Patel, has chosen Supernus as the first company to cover due to its impressive transformation and growth potential in the CNS sector [2].